IMP4927

IMP4927 is a small-molecule drug developed by Impact Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: IMP4297 tablet.The starting dose from 100mg QD. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04169997 (A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer), in ovarian cancer. The largest, NCT04169997, plans to enrol 404 participants (actual) with primary completion expected 2023-03-16. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.